Hsiri Therapeutics is a biotechnology company developing therapies for infections caused by drug-resistant bacteria and fungi, with particular attention to tuberculosis and nontuberculous mycobacterial disease. Its discovery work originated at the University of Notre Dame and Montana State University, and its research laboratories are in South Bend, Indiana, alongside collaborations in Montana and Singapore. The company has received support from the Department of Defense and the National Institutes of Health and has entered research and licensing collaborations with Shionogi.
Kinnear Pharmaceuticals, LLCKinnear Pharmaceuticals is a preclinical-stage biotechnology company developing Ceragenin-based anti-infective and anti-inflammatory therapies, with its lead candidate CSA-131 aimed at difficult infections associated with cystic fibrosis. The Las Vegas company’s proprietary platform, based on research invented at Brigham Young University, uses synthetic non-peptide molecules modeled on the innate immune peptide LL-37. Kinnear is a subsidiary of N8 Biosciences and received FDA Qualified Infectious Disease Product designation for CSA-131 in 2023.EASTON, MD
Biaera Technologies, LLCFounded in 2003 by former USAMRIID aerosol research director Dr. Justin M. Hartings, Hagerstown-based Biaera Technologies develops fully automated, turnkey and custom inhalation systems for laboratory infectious-disease research. Its patented aerosol-control platforms integrate laboratory equipment and exposure systems, supporting research programs at government, military, university and independent laboratories worldwide.HAGERSTOWN, MD
BioSherpa, LLCBioSherpa, LLC develops the BioSherpa Specimen Transport System, a biofilm-reducing diagnostic agent designed to help laboratories culture infectious pathogens even after patients have received antibiotics. The system grew from infectious-disease research conducted by founders Tom Cumbo and Destin Radder in Nepal and Peru, and was later developed with physician and former Army officer Christopher Hutson. Its research includes cases where BioSherpa STS identified pathogens missed by standard collection methods, including a case involving three days of effective antibiotic treatment.LEWISTON, NY